Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 5/20 | 0.59 |
| ▸ | KCNJ5 | P48544 | 5/20 | 0.59 |
| ▸ | KCNJ3 | P48549 | 5/20 | 0.59 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050389 | 0.89 | P2RY12 (0.61) | KCNJ6KCNJ5KCNJ3P2RY12MAPK14 | |
| SCHEMBL16317149 | 0.88 | P2RY12 (0.56) | KCNJ6KCNJ5KCNJ3P2RY12MAPK14 | |
| SCHEMBL2080486 | 0.85 | MAPK14 (0.58) | KCNJ6KCNJ5KCNJ3P2RY12MAPK14 | |
| SCHEMBL4055653 | 0.84 | PTPN1 (0.67) | KCNJ6KCNJ5KCNJ3P2RY12MAPK14 | |
| SCHEMBL2083568 | 0.83 | MAPK14 (0.63) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL4111911 | 0.79 | TRPV1 (0.75) | TRPV1NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL4048881 | 0.79 | MAPK14 (0.56) | KCNJ6KCNJ5KCNJ3P2RY12MAPK14 | |
| SCHEMBL4052022 | 0.77 | MAPK14 (0.64) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL2083858 | 0.76 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL3188430 | 0.75 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1836173-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | KCNJ6 4281/4885KCNJ5 4370/4885KCNJ3 4438/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | KCNJ6 2415/4885KCNJ5 2659/4885KCNJ3 2494/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | KCNJ6 4192/4885KCNJ5 4319/4885KCNJ3 4273/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | KCNJ6 3243/4885KCNJ5 3284/4885KCNJ3 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.